GT BIOPHARMA, INC. Accounts Payable, Interest-bearing, Interest Rate
GT BIOPHARMA, INC. (GTBP) had Accounts Payable, Interest-bearing, Interest Rate of 100.00% as of 2025-09-30, per its 10-Q/A filed 2026-03-06.
Financial Statements › Notes › Payables and Accruals
us-gaap:AccountsPayableInterestBearingInterestRate · last filed 2026-03-06
- 2025-09-30: Accounts Payable, Interest-bearing, Interest Rate 100.00%.
- 2025-06-30: Accounts Payable, Interest-bearing, Interest Rate 100.00%.
- 2025-03-31: Accounts Payable, Interest-bearing, Interest Rate 100.00%.
- 2024-12-31: Accounts Payable, Interest-bearing, Interest Rate 100.00%; Accounts Payable, Interest-bearing, Interest Rate as first filed 12.00%.
| Period end | Accounts Payable, Interest-bearing, Interest Rate | Accounts Payable, Interest-bearing, Interest Rate as first filed |
|---|---|---|
| 2025-09-30 | 100.00% 10-Q/A · filed 2026-03-06 | |
| 2025-06-30 | 100.00% 10-Q/A · filed 2026-03-06 | |
| 2025-03-31 | 100.00% 10-Q · filed 2025-05-15 | |
| 2024-12-31 | 100.00% 10-Q/A · filed 2026-03-06 | 12.00% 10-K · filed 2025-02-21 |
| 2023-12-31 | 13.00% 10-K · filed 2025-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |